Диссертация (1140686), страница 19
Текст из файла (страница 19)
Genetic polymorphism of cytochromesP450 2C9 and 2C19 in Slovenian population // Zdrav. Vestn. – 2003. – 72. – p. 347351.54. Higgins CF, Gottesman MM. Is the multidrug transporter a flippase? // TrendsBiochem Sci. – 1992. – 17. – p. 18- 21.55. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, Johne A,Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U.Functional polymorphismsof the human multidrug-resistance gene: multiple sequence variations and correlation ofone allele with P-glycoprotein expression and activity in vivo // Proc Natl Acad SciUSA. – 2000. – 97. – p.
3473–8.56. Inaba M, Kobayashi H, Sakurai Y, Johnson RK.Active efflux of daunorubicinand adriamycin in sensitive and resistant sublines of P388 leukemia // Cancer Res. –1979. – 39(6 Pt 1). – p. 2200-3.57. Jażdżyk M, Sałagacka A, Zebrowska M, Balcerczak M, Mirowski M,Balcerczak E.ABCB1 expression in peptic ulcer patients and its connection with H.pylori Infection // Ann Clin Lab Sci. – 2014. – 44(3). – p.
294-7.58. Juliano RL, Ling V.A surface glycoprotein modulating drug permeability inChinese hamster ovary cell mutants // Biochim Biophys Acta. – 1976. – 455(1). – p.152-62.59. Klein T.E. et al. Estimation of the warfarin dose with clinical andpharmacogenetic data // N. Engl. J. Med.
– 2009. – 360. – p. 753–764.60. Komoto C, Nakamura T, Sakaeda T, Kroetz DL, Yamada T, Omatsu H,Koyama T, Okamura N, Miki I, Tamura T, Aoyama N, Kasuga M, Okumura K. MDR1haplotype frequencies in Japanese and Caucasian, and in Japanese patients with125colorectal cancer and esophageal cancer // Drug Metab Pharmacokinet. – 2006. – 21(2).– p. 126-32.61. Kroetz DL, Pauli-Magnus C, Hodges LM, Huang CC, Kawamoto M, JohnsSJ, Stryke D, Ferrin TE, DeYoung J, Taylor T, Carlson EJ, Herskowitz I, GiacominiKM, Clark AG.Sequence diversity and haplotype structure in the human ABCB1(MDR1, multidrug resistance transporter) gene // Pharmacogenetics.
– 2003. – 13(8). –p. 481-94.62. KurzawskiM.,Gawrońska-SzklarzB.,WrześniewskaJ.EffectofCYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients //Eur J Clin Pharmacol. – 2006. – 62(10). – p. 877-80.63. Lehmann DF, Medicis JJ, Franklin PD. Polymorphisms and the pocketbook:the cost-effectiveness of cytochrome P450 2C19 genotyping in the eradication ofHelicobacter pylori infection associated with duodenal ulcer // J Clin Pharmacol.
–2003. – 43(12). – p. 1316-23.64. Malfertheiner P, et al. Management of Helicobacter pylori infection—theMaastricht V/Florence Consensus Report // Gut. – 2017. – 66. – p. 6–30.65. Malfertheiner P., Megraud F., O’Morain C.A., et al. Management ofHelicobacter pylori infection – the Maastricht V/ Florence Consensus Report // Gut. –2016. – 0.
– p. 1–24.66. Marzolini C, Paus E, Buclin T, Kim RB.Polymorphisms in human MDR1 (Pglycoprotein): recent advances and clinical relevance // Clin Pharmacol Ther. – 2004. –75(1). – p. 13-33.67. McNicholl AG, Linares PM, Nyssen OP, Calvet X, Gisbert JP (2012) Metaanalysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in thetreatment of Helicobacter pylori infection // Aliment Pharmacol Ther. – 36.
– p. 414–425.68. Medline PubMed, URL: http://www.ncbi.nlm.nih.gov/pubmed69. Midolo PD, Turnidge JD, Lambert JR, Bell JM. Oxygen concentrationinfluences proton pump inhibitor activity against Helicobacter pylori in vitro //Antimicrob Agents Chemother. – 1996. – 40(6). – p. 1531-3.12670. Noubarani M, Kobarfard F, Motevalian M, Keyhanfar F. Variation inomeprazole pharmacokinetics in a random Iranian population: a pilot study // Biopharm.Drug Dispos. – 2012. – 33.
– p. 324–331.71. Ohlsson Rosenborg S, Mwinyi J, Andersson M, Baldwin RM, Pedersen RS,Sim SC, Bertilsson L, Ingelman-Sundberg M, Eliasson E.Kinetics of omeprazole andescitalopram in relation to the CYP2C19*17 allele in healthy subjects // Eur J ClinPharmacol. – 2008. – 64(12). – p. 1175-9.72. Ohnishi A, Murakami S, Akizuki S, Mochizuki J, Echizen H, Takagi I.In vivometabolic activity of CYP2C19 and CYP3A in relation to CYP2C19 geneticpolymorphism in chronic liver disease // J Clin Pharmacol. – 2005. – 45(11).
– p. 12219.73. Omar M, Crowe A, Parsons R, Ee H, Tay CY, Hughes J. P-glycoproteinexpression in Helicobacter pylori-positive patients: the influence of MDR1 C3435Tpolymorphism // J Dig Dis. – 2012. – 13. – p. 414-420.74. Padol S, Yuan YH, Thabane M, Padol IT, Hunt RH. The effect of CYP2C19polymorphisms on H.pylori eradication rate in dual and triple first-line PPI therapies: Ameta-analysis // Am J Gastroenterol.
– 2006. – 101. – p. 1467–1475.75. Payan M., Rouini M.R., Tajik N. et al. Hydroxylation index of omeprazole inrelation to CYP2C19 polymorphism and sex in a healthy Iranian population // Daru. –2014. – 22. – pp. 81.76. Puris E, Pasanen M, Gynther M, Häkkinen MR, Pihlajamäki J, Keränen T,Honkakoski P, Raunio H, Petsalo A.A liquid chromatography-tandem massspectrometry analysis of nine cytochrome P450 probe drugs and their correspondingmetabolites in human serum and urine // Anal Bioanal Chem.
– 2017. – 409(1). – p.251-268.77. Sapone A., Vaira D., Trespidi S. et al. The clinical role of cytochrome P450genotypes in Helicobacter pylori management // Am J Gastroenterol. – 2003. – 98(5). –p. 1010-5.12778. Scordo MG Caputi AP, D'Arrigo C, Fava G, Spina E. Allele and genotypefrequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population // Pharmacol.Res. – 2004. – 50 (2). – p. 195-200.79. Scott D, Weeks D, Melchers K, Sachs G.The life and death of Helicobacterpylori.Gut. 1998;43 Suppl 1:S56-60; Scott DR, Weeks D, Hong C, Postius S, MelchersK, Sachs G.The role of internal urease in acid resistance of Helicobacter pylori //Gastroenterology. – 1998.
– 114(1). – p. 58-70.80. Scott SA, Sangkuhl K, Stein CM, et al. Clinical PharmacogeneticsImplementation Consortium. Clinical Pharmacogenetics Implementation Consortiumguidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update // ClinPharmacol Ther. – 2013. – 94(3). – p. 317-323.81. Shirai N., Furuta T., Moriyama Y., et al. Effects of CYP2C19 genotypicdifferences in the metabolism of omeprazole and rabeprazole on intragastric pH //Aliment Pharmacol Ther. – 2001.
– 15. – p. 1929-37.82. Sim S., Risinger C., Dahl M.L. et al. Сommon novel CYP2C19 gene variantcauses ultrarapid drug metabolism relevant for the drug response to proton pumpinhibitors and antidepressants // Clin. Pharmacol. Ther. – 2006. – 79 (1). – p. 103-113.83. Simon W.A., Büdingen C., Fahr S. et al.
The H+, K+ - ATPase inhibitorpantoprazole (BY1023/SK&F96022) interacts less with cytochrome P450 thanomeprazole and lansoprazole // Biochem Pharmacol. – 1991. – 42(2). – p. 347–355.84. Sugimoto M., Furuta T., Shirai N. et al. Treatment strategy to eradicateHelicobacter pylori infection: impact of pharmacogenomics-based acid inhibitionregimen and alternative antibiotics // Expert Opin Pharmacother. – 2007. – 8(16). – p.2701-17.85. Svedlund J, Sjodin I, Dotevall G.
GSRS – a clinical rating scale forgastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcerdisease // Dig Dis Sci. – 1988. – 33. – p. 129–34.86. Swen JJ, Nijenhuis M, de Boer A et al. Pharmacogenetics: from bench tobyte--an update of guidelines // Clin Pharmacol Ther. – 2011. – 89(5).
– p. 662-73.12887. Swen, J.J. et al. Pharmacogenetics: from bench to byte // Clin. Pharmacol.Ther. – 2008. – 83. – p. 781–787.88. Sychev DA, Shuev GN, Suleymanov SS, Ryzhikova KA, Mirzaev KB,Grishina EA, Snalina NE, Sozaeva ZA, Grabuzdov AM, Matsneva IA. Comparison ofCYP2C9, CYP2C19, CYP2D6, ABCB1, and SLCO1B1 gene-polymorphism frequencyin Russian and Nanai populations // Pharmgenomics Pers Med. – 2017. – 10.
– p. 93-99.89. Tamminga WJ, Wemer J, Oosterhuis B, de Zeeuw RA, de Leij LF, JonkmanJH. The prevalence of CYP2D6 and CYP2C19 genotypes in a population of healthyDutch volunteers // Eur J Clin Pharmacol. – 2001. – 57 (10). – p. 717-22.90. Tanaka S, Uchida S, Inui N, Takeuchi K, Watanabe H, NamikiN.Simultaneous LC-MS/MS analysis of the plasma concentrations of a cocktail of 5cytochrome P450 substrate drugs and their metabolites // Biol Pharm Bull. – 2014. –37(1).
– p. 18-25.91. Tang HL, Li Y, Hu YF, Xie HG, Zhai SD. Effects of CYP2C19 loss-offunction variants on the eradication of H. pylori infection in patients treated with protonpump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinicaltrials // PLoS One. – 2013. –8(4). – e62162.92.
The Human Cytochrome P450 (CYP) Allele Nomenclature Database,93. URL: http://www.cypalleles.ki.se94. Wang D, Johnson AD, Papp AC, Kroetz DL, Sadée W.Multidrug resistancepolypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability //Pharmacogenet Genomics. – 2005. – 15(10). – p.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
